An Italian study suggests the weight-loss drug ingredient liraglutide may significantly reduce migraine frequency. Researchers found that 31 obese adults with chronic migraines experienced a 50% reduction in migraine days after three months of treatment. The study, published in the journal Headache, posits that liraglutide's impact may stem from its effect on cerebrospinal fluid pressure, not solely weight loss. While promising, the study's small sample size necessitates further research to confirm these findings and explore long-term effects.

Prepared by Olivia Bennett and reviewed by editorial team.